Press Releases Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-10 pm EDT			5-day change	1st Jan Change
2.267 ^USD	-11.11%		-18.17%	-32.34%

May. 07	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyclerion Appoints Regina Graul, Ph.D., as President	Dec. 04	AQ
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	Nov. 30	AQ
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	23-08-01	AQ
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	23-07-31	AQ
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-06-01	AQ
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	23-06-01	AQ
Cyclerion Therapeutics : Private Placement - Form 8-K	23-05-25	PU
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-05-25	AQ
Cyclerion Announces Reverse Stock Split	23-05-15	GL
CYCLERION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	23-05-12	AQ
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	23-05-11	GL
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	23-05-11	GL
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	23-05-11	AQ
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	23-05-11	AQ
CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-04-03	AQ
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement	23-04-03	GL
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement	23-04-03	GL
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases	23-03-27	GL
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases	23-03-27	AQ
CYCLERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Press Releases

Filters